Physician profile
Daniel Das
NPI 1679142905
$274.20
in general payments reported to CMS, 2019-2025
10 companies · $87.86 in 2025
The $87.86 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $84.85 · 2024: $101 · 2025: $87.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $274.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $274.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.03 | 2023-2025 | Zerbaxa, Segluromet, Steglatro |
| Amgen INC. | $34.72 | 2023-2024 | Krystexxa, Repatha |
| Viatris Specialty LLC | $32.64 | 2025 | Yupelri |
| Edwards Lifesciences Corporation | $30.66 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ucb, INC. | $24.84 | 2024 | Cimzia |
| Janssen Biotech, INC. | $24.59 | 2024 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.42 | 2025 | Xifaxan |
| Recordati_rare_diseases_inc. | $21.58 | 2023 | Isturisa, Signifor Lar |
| Actelion Pharmaceuticals US, INC. | $19.22 | 2024 | Uptravi, Opsumit |
| Sobi, INC | $14.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.